Roivant announces FDA approval for LISRAYA in dermatomyositis
Roivant said the FDA approved LISRAYA (brepocitinib) for adults with dermatomyositis and it is now available in the U.S.
Story updates
07:37:38 PM UTC
SquawkNews
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.